Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emanuela Romagnoli

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Frontiers in Genetics

Genetics

Molecular Medicine

2020

English

Related publications

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

2020

English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde

English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget

Oncology

2017

English

Management of Adverse Events During Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer

Therapeutic Advances in Medical Oncology

Oncology

2018

English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry

English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology

Medicine

Oncology

2018

English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology

Cancer Research

Oncology

2018

English

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease

2018

English

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emanuela Romagnoli

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Related publications

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Management of Adverse Events During Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer